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Abstract 
Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by progressive fibrosis of the skin 
and the internal organs. In a previous work we suggested a correlation between levels of salivary psoriasin (S100A7) 
and pulmonary involvement in SSc patients. The goals of this study are to determine the distribution characteristics 
of psoriasin in whole saliva (WS) of SSc and healthy donor populations and define its predictive value on diffusion 
capacity of carbon monoxide (DLCO), along with others clinical parameters.
Methods: Salivary level of psoriasin was determined by ELISA kit in 134 SSc patients, 63 Raynaud syndrome patients, 
40 patients affected by other connective diseases (non-case) and 74 healthy control subjects.
Results: A significant increase of salivary psoriasin was observed in SSc patients when compared with other healthy 
and pathological controls. Moreover, we confirmed the efficacy of salivary psoriasin to correlate with DLCO in a large 
cohort of SSc patients.
Conclusions: Overall our results suggest a rapid, non invasive and low costing method which can help clinicians in 
the evaluation of SSc pulmonary involvement.
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Background
Human psoriasin (S100A7) is a small calcium binding 
protein which belongs to the multigenic S100 family of 
EF-hand proteins [1, 2]. Human psoriasin was originally 
identified as an 11.4 kDa protein upregulated in inflamed 
hyperplastic psoriatic skin [3] where it acts as chemoat-
tractant for T-cells to amplify inflammatory response in 
psoriasis. Recently, an highly homologous (93 % of iden-
tity) protein, koebnerisin (S100A15) [4], was also identi-
fied as up-regulated in psoriasis, thereby suggesting a role 
in the inflammatory phenotype. Nonetheless, a recent 
work of Wolf and coworkers [4] reveals an unexpected 
biological diversity into properties and functional mecha-
nisms of psoriasin and koebnerisin to induce inflamma-
tion suggesting a functional synergism in inflammatory 
diseases. In fact, despite their high homology, both anti-
microbial peptides psoriasin and koebnerisin are differ-
entially regulated by different cell types in the skin and 
have distinct proinflammatory functions and mecha-
nisms of action [5]. Nonetheless they acts synergistically 
as “alarmins” to prime skin cells for production of immu-
notropic cytokines, particularly the Th17 cytokines, that 
further amplify the inflammatory response. On the other 
hand, recent researches on Th17 function have associated 
cytokines in the development and pathogenesis of auto-
immune diseases such as SSc and rheumatoid arthritis 
(RA) [5]. Focusing on pulmonary manifestations of SSc 
disease serum levels of some cytokines, i.e. IL-17, IL-21 
and IL-23, [6] and serum amyloid A [7] have been linked 
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to lung involvement and have been suggested as potential 
biomarkers for this complication.
In a previous study using a proteomic approach, we 
have shown an association of salivary psoriasin with 
SSc clinical manifestations suggesting 12  kDa psoria-
sin as a potential predictor of pulmonary involvement 
[8]. The novelty of our findings was the detection of 
marker in whole saliva (WS) whose sampling is a non-
invasive, simple, safe and stress-free procedure that 
can be applied to large groups of subjects. Starting 
from preliminary results, in this work we extended the 
evaluation of the presence of salivary psoriasin and its 
correlation with clinical parameters in a large cohort 
of SSc patients. Therefore the aims of this study were: 
(1) to determine salivary psoriasin concentrations by a 
specific ELISA kit; (2) to define the distribution charac-
teristics of salivary psoriasin levels in SSc patient and 
healthy subject populations by SPSS statistic analysis; 
(3) to confirm the correlation of the presence of sali-
vary psoriasin with pulmonary involvement in the SSc 
population.
Patients and methods
Patients
One hundred thirty-four consecutive adult patients 
with diagnosis of SSc (16 male, 118 female; median 
age 55.4  ±  13.1 years), enrolled between January 2009 
and June 2011, were included in the study. The study 
was approved by Local Ethics Committee. All patients 
met the ACR criteria [9]. WS samples were obtained 
at scheduled visits after patients signed consent form 
approved by Local Ethics Committee. WS was also col-
lected from sixty-three patients with Raynaud syndrome 
(8 male, 55 female; median age 51.3 ± 16.7 years), forty 
patients affected by other connective diseases (non-case) 
(20 male, 20 female; median age 54.8 ±  12.1 years) and 
seventy-four healthy volunteers (14 male, 60 female; 
median age 40.2  ±  20.7 years). The clinical features of 
SSc patients are summarized in Table 1. Patients affected 
by Raynaud’s syndrome (24 primary and 30 secondary) 
and noncase patients (8 Undifferentiated Connective Tis-
sue Disease (UCTD), 2 Sjogren’s syndrome, 17 psoriasis, 
4 morphea, 4 polymyalgia, 1 myositis, 2 dermatomyositis, 
1 rheumatoid arthritis, 1 microangiopathy), represented 
the pathological controls.
Ethics statements
The research was carried out according to The Code of 
Ethics of the World Medical Association (Declaration of 
Helsinki), and the author’s institutional review board has 
approved the study. This study was approved by the Local 
Ethics Committee (Comitato per la Sperimentazione 
Clinica dei Farmaci, Azienda Ospedaliera Universitaria 
Pisana) and signed consent forms were obtained from all 
patients before their enrolment in the study.
Sample collection and preparation
WS samples were collected early in the morning in 
standard conditions, as previously described [10]. Briefly, 
in order to minimize protein degradation, the samples 
were processed immediately and kept on ice during the 
process. To remove debris and cells, centrifugation at 
14,000g for 30  min at 4  °C was performed and samples 
were stored at −80 °C until assayed.
Salivary psoriasin assay
The concentration of S100A7 in WS was detected 
by enzyme linked immunosorbent assay (ELISA) kit 
(CircuLex™, cat# CY-8073) according to manufacturer’s 
instructions. Briefly, samples (1:4000 dilution) and stand-
ards (ranging from 0.12 to 90 ng/ml) were added in the 
wells. After incubation and washing, horseradish peroxi-
dase (HRP) conjugated antibody was added, incubated 
and then wells were washed before the addition by sub-
strate reagent. The reaction was stopped and the plate 
read at 450 nm using a microplate-reader Wallac Victor 
1420 (PerkinElmer, San Diego, CA, USA) The limit of 
detection was better than 0.12 ng/ml of sample.
Statistical analysis
The normality of distribution of psoriasin levels was 
determined by Kolmogorov–Smirnov test. Due to 
Table 1 SSc patient’s clinical and serological features
DLCO diffusion capacity of carbone monoxide, HRCT high resolution computed 
tomography
Features Data (%)
No. of patients 134
Age, years (mean ± SD) 55.4 ± 13.1
Gender (M, F) 16 M, 118 F
Diffuse 44 (38)
Limited 71 (62)
Scl-70 36 (27)
ACA 47 (36)
FAN Hep2 109 (83)
Acral ulcers 28 (24)
Skin 74 (87)
Rodnan skin score 9 ± 7.3
Pattern capillaroscopy 87 (78)
Heart involvement 22 (19)
Kidney involvement 8 (7)
DLCO <70 49 (42)
Lung fibrosis (HRCT) 58 (47)
Pulmonary hypertension 11 (9)
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non-normal distribution of the data, non parametric test 
(Mann–Whitney U test) was used to compare psoriasin 
levels. Spearman’s rank correlations were calculated to 
determine the correlation between psoriasin levels and 
various clinical and laboratory parameters. Data were 
analyzed using IBM SPSS Statistics Version 19. p < 0.05 
was considered statistically significant. Receiver operat-
ing characteristic (ROC) curve was performed to assess 
the sensitivity and specificity (IBM SPSS Statistics Ver-
sion 19).
Results and discussion
The current report focuses on salivary levels of psoriasin 
protein in patients with SSc and their association with 
clinical and serological parameters, particularly with 
lung impairment. Pulmonary involvement is the most 
common manifestation of SSc. Usually, measurement of 
carbon monoxide diffusing capacity (DLCO), together 
with high-resolution computed tomography (HRTC), are 
initial pulmonary function tests in the evaluation of lung 
impairment. Nonetheless, recently Suliman and cow-
orkers [11] have shown that the use of only pulmonary 
function tests as the screening method for SSc-interstitial 
lung disease, gives a high risk of missing significant rate 
of false–negative results. Previously, using a proteomic 
approach, we have shown several S100 proteins are 
altered in SSc WS including S100A7 (psoriasin) [8, 12]. 
In particular, we have shown that high levels of salivary 
psoriasin correlate with the severity of lung involvement 
of SSc patients. Likely, also Lakota et al. [7] have shown 
a correlation between high levels of serum amyloid A 
protein and pulmonary involvement in SSc suggest-
ing a potential role of this protein as biomarker for this 
complication.
In this study, using an ELISA test, a quantification of 
psoriasin level in WS of SSc patients compared with that 
of healthy and pathological control subjects was per-
formed. Psoriasin levels were analyzed using SPSS in dif-
ferent groups of subjects and a non normal distribution 
was observed. The mean values ±  SE were 14.1 ±  1.3, 
25.5 ± 2.2, 19.0 ± 3.8 and 12.1 ± 3.3 µg/ml for healthy, 
SSc, Raynaud and noncase groups, respectively. Figure 1 
shows the scatter dot plot of psoriasin concentrations 
in different classes of patients. Highly significant differ-
ence (p < 0.0001****) of expression was observed in SSc 
with respect to all other groups. No significant differ-
ence in psoriasin levels were detected between two clini-
cal subtypes [diffuse SSc (dSSc) and limited SSc (lSSc)] 
(p = 0.73) (Fig. 2). The diagnostic power of psoriasin has 
been also analyzed. ROC curve was calculated to evalu-
ate the ability of psoriasin to separate healthy and SSc 
groups (Fig. 3). The sensitivity and specificity of psoria-
sin were 68 and 66 %, respectively and the derived area 
Fig. 1 Psoriasin level were determined in SSc patients, healthy 
subjects and pathological controls. Bold horizontal lines represent the 
mean value
Fig. 2 Psoriasin levels in the clinical SSc subtypes. Bold horizontal lines 
represent the mean value
Fig. 3 Receiver operate characteristic (ROC) curve of psoriasin in SSc 
vs healthy subjects
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under curve (AUC) was 0.71. Moderate values of sen-
sitivity and specificity derived from the ROC analysis 
performed in a large cohort of SSc patients, confirmed 
our previous observation that psoriasin is not suitable as 
early diagnostic biomarker of SSc [8]. However, Spear-
man’s analysis showed a direct correlation of psoriasin 
level with the presence of serological ACA (r  =  0.264, 
p = 0.002**) and with DLCO (r = 0.186, p = 0.045*). No 
significant correlations were detected for psoriasin with 
other clinical and serological parameters taken in con-
sideration (Table 2). Although we did not observe a sta-
tistically significant correlation of psoriasin levels with 
HRCT, however the significant correlation with DLCO, a 
functional pulmonary parameter, suggests that the assay 
of psoriasin in saliva might be a non invasive tool use-
ful to strengthen the outcome of SSc. The pathogenetic 
relationship between psoriasin and lung impairment is 
still far from being completely clarified. As far as psoria-
sin is concerned different intracellular and extracellular 
functions have been suggested for this protein, includ-
ing regulation of calcium homeostasis, cell prolifera-
tion, differentiation, apoptosis, cell invasion and motility, 
cytoskeleton dynamics, protein phosphorylation, regu-
lation of transcriptional factors, immune responses, 
chemotaxis, antimicrobial, and inflammation [13]. In 
particular, a role of chemoattractant agents which are 
able to stimulate the neutrophyl and CD4+  T lympho-
cyte infiltration has been hypothesized by us to explain 
the link between psoriasin and lung involvement [8]. At 
this regard recently, the roles of Th17 and regulatory T 
(Treg) cells, in the autoimmune disease pathogenesis 
and in particular in SSc have been investigated [14]. In 
Table 2 Clinical correlations
The significant correlations of psoriasin with clinical parameters are in italics
r correlation coefficient, n number of subjects, DLCO diffusion capacity of carbon monoxide, HRCT high resolution computed tomography
Statistical significance level: * p < 0.05
** p < 0.01
Non-parametric  
correlations
Psoriasin  
(µg/ml)
Acral  
ulcers
Skin ACA SCL70 DLCO Lung 
fibrosis 
(HRTC)
Rho Spearman
 Psoriasin (µg/ml)
  r 1.000 0.032 0.019 0.264 −0.150 0.186 0.117
  p value 0.0 0.730 0.860 0.002** 0.084 0.045* 0.199
  n 134 121 90 133 133 117 122
 Acral ulcers
  r 0.032 1.000 0.219 0.053 0.093 0.186 0.132
  p value 0.730 0.0 0.039* 0.566 0.311 0.053 0.161
  n 121 121 89 121 121 109 114
 Skin
  r 0.019 0.219 − −0.128 0.089 0.256 0.095
  p value 0.860 0.039* 0.0 0.228 0.406 0.019* 0.389
  n 90 89 90 90 90 84 85
 ACA
  r 0.264 0.053 −0.128 1.000 −0.467 −0.164 −0.336
  p value 0.002** 0.566 0.228 0.0 0.000** 0.078 0.000**
  n 133 121 90 133 133 117 122
 SCL70
  r −0.150 0.093 0.089 0.467 1.000 0.265 0.350
  p value 0.084 0.311 0.406 0.000** 0.0 0.004** 0.000**
  n 133 121 90 133 133 117 122
 DLCO
  r 0.186 0.186 0.256 −0.164 0.265 1.000 0.451
  p value 0.045* 0.053 0.019* 0.078 0.004** 0.0 0.000**
  n 117 109 84 117 117 117 113
 Lung fibrosis (HRTC)
  r 0.117 0.132 0.095 0.336 0.350 0.451 1.000
  p value 0.199 0.161 0.389 0.000** 0.000** 0.000** 0.0
  n 122 114 85 122 122 113 122
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fact, Jiang and coworkers have shown that elevated Treg 
(CD4, CD25 and Foxp3 positive) cells are observed in 
SSc patients with a high interstitial lung disease score 
and low DLCO value. Moreover, the authors have sug-
gested that Th17 cells participate in both inflammation 
and fibrosis by secreting IL-17, which is a potent inducer 
of several antimicrobial peptides and proteins such as 
psoriasin [14]. Therefore, we reinforce our previous sug-
gestion that the increase of psoriasin level observed in 
SSc patients could be linked with T cell abnormalities 
and consequent alteration in the secretion of peculiar 
cytokines which are leading factors SSc pathogenesis 
and lung impairment [6, 14].
Overall our results confirm the increase of psoriasin 
in WS of SSc patients also when compared with patho-
logical controls and its correlation with DLCO and 
ACA but not with the presence of anti-Scl-70 antibod-
ies (p = 0.089) and lung fibrosis (p = 0.199) as previously 
suggested [8].
Conclusions
The strength of our study includes the detection of 
marker in WS whose sampling is a noninvasive, simple, 
safe and stress-free procedure that can be applied to large 
group of subjects. On the other and the power of saliva as 
potential diagnostic fluid is largely documented consid-
ering numerous advantages with respect the serum [15–
18]. Moreover, the assay of salivary psoriasin could be a 
rapid method allowing clinicians to assess the pulmonary 
involvement, which until now is revealed only by the use 
of more invasive and expensive instrumental investiga-
tions. Finally, we think that a future development could 
be the introduction of a point of care test for the realiza-
tion of a rapid, simple, low-cost and accurate method of 
psoriasin directly from saliva.
Abbreviations
SSc: systemic sclerosis; WS: whole saliva; DLCO: diffusion capacity of carbon 
monoxide; RA: rheumatoid arthritis; UCTD: undifferentiated connective tissue 
disease; ELISA: enzyme linked immunoassorbent assay; HRP: horseradish 
peroxidase; ROC: receiver operating characteristic; HRTC: high-resolution com-
puted tomography; AUC: area under curve; dSSc: diffuse SSc; lSSc: limited SSc.
Authors’ contributions
LG, AL designed the study, coordinated the research, and with MRM analyzed 
data and wrote the manuscript; FS, ED and FC carried out psoriasin assay; CG 
and GG carried out the clinical biochemical analysis; LB carried out the clinical 
evaluation of the patient, participated in the design and coordination of study 
and helped to draft the manuscript. All authors read and approved the final 
manuscript.
Author details
1 Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy. 
2 Department of Clinical and Experimental Medicine, University of Pisa, Via 
Roma 67, 56126 Pisa, Italy. 
Acknowledgements
None.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The data are included in the article as figures and tables.
Ethics approval and consent to participate
The study was approved by the Local Ethics Committee (Comitato per la 
Sperimentazione Clinica dei Farmaci, Azienda Ospedaliera Universitaria Pisana) 
and in accordance with Declaration of Helsinki.
Funding
This study was supported by the “Fondazione Cassa di Risparmio di Pisa.”
Received: 31 May 2016   Accepted: 29 August 2016
References
 1. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL. Func-
tion of S100 proteins. Curr Mol Med. 2013;13:24–57.
 2. Heizmann CW, Fritz G, Schäfer BW. S100 proteins: structure, functions and 
pathology. Front Biosci. 2002;7:d1356–68.
 3. Madsen P, Rasmussen HH, Leffers H, Honoré B, Celis JE. Molecular clon-
ing, occurrence, and expression of a novel partially secreted protein 
“psoriasin” that is highly up-regulated in psoriatic skin. J Invest Dermatol. 
1991;97:701–12.
 4. Wolf R, Ruzicka T, Yuspa SH. Novel S100A7 (psoriasin)/S100A15 (koeb-
nerisin) subfamily: highly homologous but distinct in regulation and 
function. Amino Acids. 2011;41:789–96.
 5. Hegyi Z, Zwicker S, Bureik D, Peric M, Koglin S, Batycka-Baran A, Prinz JC, 
Ruzicka T, Schauber J, Wolf R. Vitamin D analog calcipotriol suppresses the 
Th17 cytokine-induced proinflammatory S100 “alarmins” psoriasin (S100A7) 
and koebnerisin (S100A15) in psoriasis. J Invest Dermatol. 2012;132:1416–24.
 6. Olewicz-Gawlik A, Danczak-Pazdrowska A, Kuznar-Kaminska B, 
Gornowicz-Porowska J, Katulska K, Trzybulska D, Batura-Gabryel H, Silny 
W, Poplawski D, Hrycaj P. Interleukin-17 and interleukin-23: importance in 
the pathogenesis of lung impairment in patients with systemic sclerosis. 
Int J Rheum Dis. 2014;17:664–70.
 7. Lakota K, Carns M, Podlusky S, Mrak-Poljsak K, Hinchcliff M, Lee J, Tomsic 
M, Sodin-Semrl S, Varga J. Serum amyloid A is a marker for pulmonary 
involvement in systemic sclerosis. PLoS ONE. 2015;10:e0110820.
 8. Baldini C, Giusti L, Bazzichi L, Ciregia F, Giannaccini G, Giacomelli C, Doveri 
M, Del Rosso M, Bombardieri S, Lucacchini A. Association of psoriasin 
(S100A7) with clinical manifestations of systemic sclerosis: is its presence 
in whole saliva a potential predictor of pulmonary involvement? J Rheu-
matol. 2008;35:1820–4.
 9. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, 
Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, 
Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes 
MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka 
O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, 
Collier DH, Csuka ME, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, 
Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope 
JE. 2013 classification criteria for systemic sclerosis: an American College 
of Rheumatology/European League against Rheumatism collaborative 
initiative. Arthritis Rheum. 2013;65:2737–47.
 10. Giusti L, Baldini C, Bazzichi L, Ciregia F, Tonazzini I, Mascia G, Giannac-
cini G, Bombardieri S, Lucacchini A. Proteome analysis of whole saliva: a 
new tool for rheumatic diseases—the example of Sjögren’s syndrome. 
Proteomics. 2007;7:1634–43.
 11. Suliman YA, Dobrota R, Huscher D, Nguyen-Kim TD, Maurer B, Jordan S, 
Speich R, Frauenfelder T, Distler O. Brief report: pulmonary function tests: high 
rate of false-negative results in the early detection and screening of sclero-
derma-related interstitial lung disease. Arthritis Rheumatol. 2015;67:3256–61.
 12. Giusti L, Bazzichi L, Baldini C, Ciregia F, Mascia G, Giannaccini G, Del 
Rosso M, Bombardieri S, Lucacchini A. Specific proteins identified in 
whole saliva from patients with diffuse systemic sclerosis. J Rheumatol. 
2007;34:2063–9.
Page 6 of 6Giusti et al. J Transl Med  (2016) 14:262 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 13. Jia J, Duan Q, Guo J, Zheng Y. Psoriasin, a multifunctional player in differ-
ent diseases. Curr Protein Pept Sci. 2014;15:836–42.
 14. Jiang N, Li M, Zeng X. Correlation of Th17 cells and CD4+CD25+ regula-
tory T cells with clinical parameters in patients with systemic sclerosis. 
Chin Med J (Engl). 2014;127:3557–61.
 15. Amado FM, Ferreira RP, Vitorino R. One decade of salivary proteom-
ics: current approaches and outstanding challenges. Clin Biochem. 
2013;46:506–17.
 16. Ciregia F, Giusti L, Da Valle Y, Donadio E, Consensi A, Giacomelli C, Sernissi 
F, Scarpellini P, Maggi F, Lucacchini A, Bazzichi L. A multidisciplinary 
approach to study a couple of monozygotic twins discordant for the 
chronic fatigue syndrome: a focus on potential salivary biomarkers. J 
Transl Med. 2013;11:243.
 17. Baldini C, Giusti L, Ciregia F, Da Valle Y, Giacomelli C, Donadio E, Ferro 
F, Galimberti S, Donati V, Bazzichi L, Bombardieri S, Lucacchini A. Cor-
respondence between salivary proteomic pattern and clinical course in 
primary Sjögren syndrome and non-Hodgkin’s lymphoma: a case report. 
J Transl Med. 2011;9:188.
 18. Bazzichi L, Ciregia F, Giusti L, Baldini C, Giannaccini G, Giacomelli C, 
Sernissi F, Bombardieri S, Lucacchini A. Detection of potential markers 
of primary fibromyalgia syndrome in human saliva. Proteom Clin Appl. 
2009;3:1296–304.
